fbpx

Aug 8, 2022

Aerie doses first patient in COMET-3 study for DED treatment

Alex Delaney-Gesing, Senior Editor
COMET-3 is the second of 3 studies in the AR-15512 Registrational Phase 3 Program, which is slated for completion by 2023.

The COMET-3 study is a randomized, double-masked, vehicle-controlled, multi-center clinical study evaluating the safety and efficacy of AR-15512—which is a TRPM8 agonist—in patients diagnosed with DED, according to a company news release.

The clinical study anticipates enrolling an estimated 460 patients at 20 sites across the US. It is designed to be identical to the COMET-2 study that began enrolling earlier this year, in May 2022. COMET-3 study patients will be randomized in a 1:1 ratio to be administered either AR-15512 (0.003%) or AR-15512 vehicle as a twice-daily dosed drop in each eye for 3 months, the release stated…..

Read more: https://www.optometrytimes.com/view/aerie-doses-first-patient-in-comet-3-study-for-ded-treatment?utm_source=sfmc&utm_medium=email&utm_campaign=08082022_OD_DOM-22-OTD0272_Eyecon-22_eNL_Dompe%20Cornea%20(NK)%20TRC_Eyecon%20text%20ad&eKey=ZG9ubmFAbWFjdWxhcmhvcGUub3Jn

Source: Optometry Times

Leave a Reply

Your email address will not be published.

Newsletter Sign-up

  • This field is for validation purposes and should be left unchanged.